AHA​ 2025 7 - 10 November 2025

Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM)

Authors :

Marianna Fontana1; Pablo Garcia-Pavia2; Martha Grogan3; Sanjiv J Shah4; Mads D M Engelmann5; G Kees Hovingh5; Arnt V Kristen6; Michelle Lim-Watson7; Brian Malling7; Soumitra Kar8; Manjunatha Revanna5; Nitasha Sarswat9; Kenichi Tsujita10 Mathew S Maurer11

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
Cardiovascular Disease
Congress oral presentation
Anti-TTR monoclonal antibody
Coramitug
PHASE 2 (RCT)